keyword
Keywords Chronic kidney disease cardiov...

Chronic kidney disease cardiovascular

https://read.qxmd.com/read/38518919/glycated-albumin-and-adverse-clinical-outcomes-in-patients-with-ckd-a-prospective-cohort-study
#21
JOURNAL ARTICLE
Mengyao Tang, Anders H Berg, Hui Zheng, Eugene P Rhee, Andrew S Allegretti, Sagar U Nigwekar, S Ananth Karumanchi, James P Lash, Sahir Kalim
RATIONALE & OBJECTIVE: HbA1c is widely used to estimate glycemia, yet it is less reliable in patients with chronic kidney disease (CKD). There is growing interest in the complementary use of glycated albumin (GA) to improve glycemic monitoring and risk stratification. However, whether GA associates with clinical outcomes in a non-dialysis dependent CKD population remains unknown. STUDY DESIGN: Prospective cohort study. SETTING: & Participants: 3110 participants with CKD from the Chronic Renal Insufficiency Cohort study...
March 20, 2024: American Journal of Kidney Diseases
https://read.qxmd.com/read/38517926/incidence-of-type-2-diabetes-cardiovascular-disease-and-chronic-kidney-disease-in-patients-with-multiple-sclerosis-initiating-disease-modifying-therapies-retrospective-cohort-study-using-a-frequentist-model-averaging-statistical-framework
#22
JOURNAL ARTICLE
Alan J M Brnabic, Sarah E Curtis, Joseph A Johnston, Albert Lo, Anthony J Zagar, Ilya Lipkovich, Zbigniew Kadziola, Megan H Murray, Timothy Ryan
Researchers are increasingly using insights derived from large-scale, electronic healthcare data to inform drug development and provide human validation of novel treatment pathways and aid in drug repurposing/repositioning. The objective of this study was to determine whether treatment of patients with multiple sclerosis with dimethyl fumarate, an activator of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, results in a change in incidence of type 2 diabetes and its complications. This retrospective cohort study used administrative claims data to derive four cohorts of adults with multiple sclerosis initiating dimethyl fumarate, teriflunomide, glatiramer acetate or fingolimod between January 2013 and December 2018...
2024: PloS One
https://read.qxmd.com/read/38517436/enrollment-in-high-deductible-health-plans-and-incident-diabetes-complications
#23
JOURNAL ARTICLE
Rozalina G McCoy, Kavya S Swarna, David H Jiang, Holly K Van Houten, Jie Chen, Esa M Davis, Jeph Herrin
IMPORTANCE: Preventing diabetes complications requires monitoring and control of hyperglycemia and cardiovascular risk factors. Switching to high-deductible health plans (HDHPs) has been shown to hinder aspects of diabetes care; however, the association of HDHP enrollment with microvascular and macrovascular diabetes complications is unknown. OBJECTIVE: To examine the association between an employer-required switch to an HDHP and incident complications of diabetes...
March 4, 2024: JAMA Network Open
https://read.qxmd.com/read/38517399/surgical-treatment-of-secondary-hyperparathyroidism-in-children-with-chronic-kidney-disease-experience-in-19-patients
#24
JOURNAL ARTICLE
Silvia Mercedes Gil, Mariana Aziz, Valeria De Dona, Laura Lopez, Maria Florencia Soto, Victor Ayarzabal, Marta Adragna, Alicia Belgorosky, Marta Ciaccio, Gisela Viterbo
OBJECTIVES: Secondary hyperparathyroidism (sHPT) is an important contributor to bone disease and cardiovascular calcifications in children with chronic kidney disease (CKD). When conservative measures are ineffective, parathyroidectomy is indicated. The aim of our study was to evaluate the efficacy and safety of subtotal parathyroidectomy (sPTX) in pediatric and adolescent patients, and to provide a rationale for considering this aggressive treatment in CKD patients with uncontrolled sHPT...
March 25, 2024: Journal of Pediatric Endocrinology & Metabolism: JPEM
https://read.qxmd.com/read/38517337/sodium-glucose-cotransporter-2-inhibitors-are-they-ready-for-prime-time-in-the-management-of-lupus-nephritis
#25
JOURNAL ARTICLE
Benjamin R Wagner, Panduranga S Rao
PURPOSE OF REVIEW: Lupus nephritis is a common complication of systemic lupus erythematosus and is associated with significant morbidity and mortality. The utility of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the management of lupus nephritis is currently uncertain. Here, we summarize the rationale for their use among patient with lupus nephritis. RECENT FINDINGS: SGLT2 inhibitors were initially developed as antihyperglycemic agents. They have since been shown to have additional, profound effects to slow the progression of chronic kidney disease and lessen the long-term risks of cardiovascular disease in large clinic trials of patients with chronic kidney disease, with and without diabetes, as well as in patients with and without proteinuria...
May 1, 2024: Current Opinion in Rheumatology
https://read.qxmd.com/read/38516524/growing-concerns-about-using-hypoxia-inducible-factor-prolyl-hydroxylase-inhibitors-for-the-treatment-of-renal-anemia
#26
REVIEW
Takeshi Nakanishi, Takahiro Kuragano
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) have emerged as a novel therapeutic class for treating anemia in patients with chronic kidney disease. Small molecule analogs of α-ketoglutarate (AKG), an essential substrate for 2-oxoglutarate-dependent dioxygenases (2-OGDDs), including prolyl hydroxylase domain proteins (PHDs), inhibit PHDs pharmacologically and thereby prevent HIF degradation. HIF stabilization alleviates anemia through several stimulatory effects on erythropoiesis, but it also affects the expression of many anemia-unrelated genes whose protein products exert important functions in vivo ...
March 2024: Clinical Kidney Journal
https://read.qxmd.com/read/38515869/pathophysiological-roles-of-the-serum-acylcarnitine-level-and-acylcarnitine-free-carnitine-ratio-in-patients-with-cardiovascular-diseases
#27
JOURNAL ARTICLE
Takafumi Nakajima, Taira Fukuda, Ikuko Shibasaki, Syotaro Obi, Masashi Sakuma, Shichiro Abe, Hirotsugu Fukuda, Shigeru Toyoda, Toshiaki Nakajima
INTRODUCTION: L-carnitine exerts protective effects, such as maintaining mitochondrial functions and decreasing reactive oxygen species, while acylcarnitine (AC) is linked to the development of heart failure and atherosclerosis. HYPOTHESIS: Serum carnitines play important pathophysiological roles in cardiovascular diseases. METHODS: Pre-operative biochemical data were obtained from 117 patients (71 men, average age 69.9 years) who underwent surgery for cardiovascular diseases...
April 2024: IJC Heart & Vasculature
https://read.qxmd.com/read/38514992/impact-of-heart-rate-changes-during-hospitalization-on-outcome-in-heart-failure-with-preserved-ejection-fraction
#28
JOURNAL ARTICLE
Dan Liu, Xiaotong Cui, Yamei Xu, Lei Xu, Zhonglei Xie, Shuai Yuan, Peng Wang, Yanyan Wang, Sanli Qian, Hui Gong, Peter Nordbeck, Jiefu Yang, Jingmin Zhou, Junbo Ge, Aijun Sun
AIMS: The benefits of lowering heart rate (HR) in heart failure (HF) with preserved ejection fraction (HFpEF) patients are still a matter of debate. This study aimed to investigate the relationship between changes in HR during hospitalization and cardiovascular (CV) events and all-cause death in hospitalized HFpEF patients. METHODS AND RESULTS: Hospitalized HF patients between January 2017 and December 2021 were consecutively enrolled in a national, multicentred, and prospective registry database, the China Cardiovascular Association Database-HF Center Registry...
March 21, 2024: ESC Heart Failure
https://read.qxmd.com/read/38513618/management-of-hyperkalemia-in-raasi-strategies-to-maintain-chronic-kidney-disease-patients-with-type-ii-diabetes-on-therapy
#29
REVIEW
Humaira A Mahmud, Biff F Palmer
BACKGROUND: According to the Centers for Disease Control and Prevention (CDC), diabetes affects approximately 37.3 million individuals in the United States (US), with another estimated 96 million people having a prediabetic state. Furthermore, one or two out of three adult Americans exhibit metabolic syndrome or an insulin-resistant state, depending on their age group. SUMMARY: Chronic Kidney Disease (CKD) represents a complication often associated with T2D or the insulin-resistant condition, typically identifiable through proteinuria...
March 21, 2024: Cardiorenal Medicine
https://read.qxmd.com/read/38512376/snf472-a-novel-therapeutic-agent-for-vascular-calcification-and-calciphylaxis
#30
REVIEW
Canlin Yang, Zhiyuan Wei, Wen Shi, Jie Xing, Xiaoliang Zhang
Vascular calcification is a common complication in patients with chronic kidney disease (CKD) and is strongly associated with an increased risk of cardiovascular events and all-cause mortality. Calciphylaxis is a specific and life-threatening manifestation of vascular calcifications that usually affects individuals with advanced kidney function impairment or those undergoing dialysis. Currently, the treatment of vascular calcification and calciphylaxis in CKD lacks approved treatments and focuses on controlling risk factors...
March 21, 2024: Journal of Nephrology
https://read.qxmd.com/read/38510194/increased-levels-of-a-mycophenolic-acid-metabolite-in-patients-with-kidney-failure-negatively-affect-cardiomyocyte-health
#31
JOURNAL ARTICLE
Eva Harlacher, Corinna Schulte, Sonja Vondenhoff, Philippe Schmitt-Kopplin, Philippe Diederich, Christian Hemmers, Julia Moellmann, Julia Wollenhaupt, Rogier Veltrop, Erik Biessen, Michael Lehrke, Björn Peters, Georg Schlieper, Christoph Kuppe, Jürgen Floege, Vera Jankowski, Nikolaus Marx, Joachim Jankowski, Heidi Noels
Chronic kidney disease (CKD) significantly increases cardiovascular risk and mortality, and the accumulation of uremic toxins in the circulation upon kidney failure contributes to this increased risk. We thus performed a screening for potential novel mediators of reduced cardiovascular health starting from dialysate obtained after hemodialysis of patients with CKD. The dialysate was gradually fractionated to increased purity using orthogonal chromatography steps, with each fraction screened for a potential negative impact on the metabolic activity of cardiomyocytes using a high-throughput MTT-assay, until ultimately a highly purified fraction with strong effects on cardiomyocyte health was retained...
2024: Frontiers in Cardiovascular Medicine
https://read.qxmd.com/read/38509984/cardiac-transcriptomic-changes-induced-by-early-ckd-in-mice-reveal-novel-pathways-involved-in-the-pathogenesis-of-cardiorenal-syndrome-type-4
#32
JOURNAL ARTICLE
Francisco Javier Munguia-Galaviz, Yanet Karina Gutierrez-Mercado, Alejandra Guillermina Miranda-Diaz, Eliseo Portilla de Buen, Mario Eduardo Flores-Soto, Raquel Echavarria
BACKGROUND: Cardiorenal syndrome (CRS) type 4 is prevalent among the chronic kidney disease (CKD) population, with many patients dying from cardiovascular complications. However, limited data regarding cardiac transcriptional changes induced early by CKD is available. METHODS: We used a murine unilateral ureteral obstruction (UUO) model to evaluate renal damage, cardiac remodeling, and transcriptional regulation at 21 days post-surgery through histological analysis, RT-qPCR, RNA-seq, and bioinformatics...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38509747/unique-characteristics-of-asians-with-hypertension-what-is-known-and-what-can-be-done
#33
JOURNAL ARTICLE
Germaine Loo, Troy Puar, Roger Foo, Tiong Kiam Ong, Tzung-Dau Wang, Quang Ngoc Nguyen, Chee Tang Chin, Calvin W L Chin
Hypertension remains the leading modifiable risk factor for cardiovascular disease worldwide. Over the past 30 years, the prevalence of hypertension has been increasing in East and Southeast Asia to a greater extent as compared with other Western countries. Asians with hypertension have unique characteristics. This can be attributed to increased impact of obesity on Asians with hypertension, excessive salt intake and increased salt sensitivity, loss of diurnal rhythm in blood pressure and primary aldosteronism...
March 1, 2024: Journal of Hypertension
https://read.qxmd.com/read/38509612/a-rapid-review-to-inform-the-policy-and-practice-for-the-implementation-of-chronic-disease-prevention-and-management-programs-for-aboriginal-and-torres-strait-islander-people-in-primary-care
#34
JOURNAL ARTICLE
Uday Narayan Yadav, Jasmine Meredith Davis, Keziah Bennett-Brook, Julieann Coombes, Rosemary Wyber, Odette Pearson
BACKGROUND: More than 35% of Aboriginal and Torres Strait Islander adults live with cardiovascular disease, diabetes, or chronic kidney disease. There is a pressing need for chronic disease prevention and management among Aboriginal and Torres Strait Islander people in Australia. Therefore, this review aimed to synthesise a decade of contemporary evidence to understand the barriers and enablers of chronic disease prevention and management for Aboriginal and Torres Strait Islander People with a view to developing policy and practice recommendations...
March 21, 2024: Health Research Policy and Systems
https://read.qxmd.com/read/38509517/investigating-the-use-of-finerenone-in-children-with-chronic-kidney-disease-and-proteinuria-design-of-the-fiona-and-open-label-extension-studies
#35
RANDOMIZED CONTROLLED TRIAL
Franz Schaefer, Giovanni Montini, Hee Gyung Kang, Johan Vande Walle, Joshua Zaritsky, Michiel F Schreuder, Mieczyslaw Litwin, Andrea Scalise, Helen Scott, James Potts, Pablo Iveli, Stefanie Breitenstein, Bradley A Warady
INTRODUCTION: Proteinuria is a modifiable risk factor for chronic kidney disease (CKD) progression in children. Finerenone, a selective, non-steroidal, mineralocorticoid receptor antagonist (MRA) has been approved to treat adults with CKD associated with type 2 diabetes mellitus (T2DM) following results from the phase III clinical trials FIDELIO-DKD (NCT02540993) and FIGARO-DKD (NCT02545049). In a pre-specified pooled analysis of both studies (N = 13,026), finerenone was shown to have an acceptable safety profile and was efficacious in decreasing the risk of adverse kidney and cardiovascular outcomes and of proteinuria...
March 21, 2024: Trials
https://read.qxmd.com/read/38508991/association-of-serum-uric-acid-with-all-cause-and-cardiovascular-mortality-in-chronic-kidney-disease-stages-3-5
#36
JOURNAL ARTICLE
Jinguo Yuan, Jin Zhao, Yunlong Qin, Yan Xing, Zixian Yu, Yumeng Zhang, Hao Wu, Qiao Zheng, Yueqing Hui, Shuxian Guo, Anjing Wang, Mei Han, Xiaoxuan Ning, Shiren Sun
BACKGROUND AND AIMS: The role of serum uric acid (SUA) in the prognosis of chronic kidney disease (CKD) is inconclusive. To explore the association of SUA level with all-cause and cardiovascular disease (CVD) mortality in patients with CKD. METHODS AND RESULTS: Leveraging data from the National Health and Nutritional Examination Survey (NHANES) and linked national death records up to December 31 2019, we explored the association of SUA with all-cause and CVD mortality using weighted cox proportional hazards regression models and restricted cubic spline (RCS) models in patients with CKD stages 3-5...
February 6, 2024: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://read.qxmd.com/read/38508877/renin-angiotensin-aldosterone-system-blockers-effect-in-chronic-kidney-disease-progression-in-hypertensive-elderly-patients-without-proteinuria-proercan-trial
#37
JOURNAL ARTICLE
A M García-Prieto, Ú Verdalles, A P de José, D Arroyo, I Aragoncillo, D Barbieri, R E Camacho, M Goicoechea
INTRODUCTION: Evidence about nefroprotective effect with RAAS blockers in elderly patients with chronic kidney disease (CKD) without proteinuria is lacking. The primary outcome of our study is to evaluate the impact of RAAS blockers in CKD progression in elderly patients without proteinuria. MATERIALS AND METHODS: Multicenter open-label, randomized controlled clinical trial including patients over 65 year-old with hypertension and CKD stages 3-4 without proteinuria...
March 19, 2024: Hipertensión y Riesgo Vascular
https://read.qxmd.com/read/38508632/finerenone-cardiovascular-and-kidney-outcomes-by-age-and-sex-fidelity-post-hoc-analysis-of-two-phase-3-multicentre-double-blind-trials
#38
RANDOMIZED CONTROLLED TRIAL
Shweta Bansal, Maria E F Canziani, Rita Birne, Stefan D Anker, George L Bakris, Gerasimos Filippatos, Peter Rossing, Luis M Ruilope, Alfredo E Farjat, Peter Kolkhof, Andrea Lage, Meike Brinker, Bertram Pitt
OBJECTIVES: This study aimed to evaluate the efficacy and safety of finerenone, a selective, non-steroidal mineralocorticoid receptor antagonist, on cardiovascular and kidney outcomes by age and/or sex. DESIGN: FIDELITY post hoc analysis; median follow-up of 3 years. SETTING: FIDELITY: a prespecified analysis of the FIDELIO-DKD and FIGARO-DKD trials. PARTICIPANTS: Adults with type 2 diabetes and chronic kidney disease receiving optimised renin-angiotensin system inhibitors (N=13 026)...
March 19, 2024: BMJ Open
https://read.qxmd.com/read/38507055/incidence-and-characteristic-of-deep-venous-thrombosis-in-hospitalized-chronic-heart-failure-patients
#39
JOURNAL ARTICLE
Jia-Lin Yuan, Wen Kang Xiao, Chao Qiong Zhang, Le Sun, Ying Kang Lin, Chuang-Xiong Hong
BACKGROUND: This study was conducted to investigate the incidence of deep venous thrombosis (DVT), outcomes and its characteristics in patients with chronic heart failure (CHF) in a retrospective setting. OUTCOMES: Patients died of cardiac shock or acute exacerbation of heart failure (HF), admitted to intensive care unit (ICU) due to acute exacerbation of HF, patients decided to withdraw treatment and return home due to acute exacerbation of HF. METHODS: From January 2015 to June 2022, we admitted 359 patients diagnosed with CHF, and lower limb ultrasonography was performed for the examination of DVT after admission...
March 20, 2024: Heart and Vessels
https://read.qxmd.com/read/38505303/the-intersection-of-atrial-fibrillation-and-coronary-artery-disease-in-middle-eastern-patients-analysis-from-the-jordan-atrial-fibrillation-study
#40
JOURNAL ARTICLE
Ayman Hammoudeh, Yahya Badaineh, Ramzi Tabbalat, Anas Ahmad, Mohammad Bahhour, Darya Ja'ara, Joud Shehadeh, Mohammad A Jum'ah, Afnan Migdad, Mohammad Hani, Imad A Alhaddad
BACKGROUND: There is a scarcity of clinical studies which evaluate the association of atrial fibrillation (AF) and coronary artery disease (CAD) in the Middle East. The aim of this study was to evaluate the impact of CAD on baseline clinical profiles and one-year outcomes in a Middle Eastern cohort with AF. METHODS: Consecutive AF patients evaluated in 29 hospitals and cardiology clinics were enrolled in the Jordan AF Study (May 2019-December 2020). Clinical and echocardiographic features, use of medications and one-year outcomes in patients with AF/CAD were compared to AF/no CAD patients...
2024: Global Heart
keyword
keyword
165769
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.